Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors
NCT07325123Phase 1Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of malic acid in solid tumor, sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoints: Adverse Events and Recommended Phase 2 Dose. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
malic acid
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07325123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325123.